Liver function study for myeloma drug cancelled before it began

NCT ID NCT04398680

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a Phase 1 study designed to see how the drug belantamab mafodotin behaves in people with multiple myeloma who also have liver impairment. The goal was to check safety and drug levels in the blood. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin
What could go wrong: The study was withdrawn before any participants were enrolled, so no data was collected. It is unclear if this treatment will be safe or effective for patients with liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Tucson, Arizona, 85724, United States
GSK Investigational Site

Beverly Hills, California, 90211, United States
GSK Investigational Site

Plantation, Florida, 33322, United States
GSK Investigational Site

Wichita, Kansas, 67214, United States
GSK Investigational Site

Baltimore, Maryland, 21201-1595, United States
GSK Investigational Site

Monroeville, Pennsylvania, 15146, United States
GSK Investigational Site

The Woodlands, Texas, 77380, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53233, United States
GSK Investigational Site

Athens, 10676, Greece
GSK Investigational Site

Daegu, 41944, South Korea
GSK Investigational Site

Hwasun, 58128, South Korea
GSK Investigational Site

Incheon, 405-760, South Korea
GSK Investigational Site

Jeonju, 561-172, South Korea
GSK Investigational Site

Pusan, 49241, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Seoul, 120-752, South Korea
GSK Investigational Site

Suwon Kyunggi-do, 16499, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.